Anna's Biostock

@gkaipale can you dm me please. Thanks.

@OptionRunners Will be great if you'll send me a message when it's open. I'm interested (depending on feature set available).

@thisworldstinks Thanks for the interest. It's actually not available right now. I'm currently working on it and should be up within the next couple of days. It will be $30/month and include a 7 day trial.

$CORT big call buyer out in August 2026

@OptionRunners Can you dm me your sub price and trial if possible

@thisworldstinks It's my site

The best and worst times to trade! $SPY $QQQ $TSLA $AAPL $NVDA

@dhovekamp42 this guy is a touch of death. Be careful to follow him. He will only lead you to the destruction of your portfolio $AFMD $ADAP $PIRS his darling stocks.

$ADAP Another @dhovekamp42 darling bites the dust. Or should people buy here Dieter? People like you should be banned for ruining so many people lives. Fing moron.

@monaco_biotech Are you holding/will you hold $CRNX through PDUFA?

@Maximus_Holla Which are the best platforms or tools to see option flows into specific names or detect unusual options flow in general and execution time as well as options strike point and volume?

Hopefully @dhovekamp42 will still pump this garbage today. $AFMD

@adar170 Imagine, you looked at things without your republican biased worldview.

Imagine if private employees would get 1/100 of sympathy gov employees getting

@adamfeuerstein @PersimmonTI If you're looking for fair choices your fourth choice could have been "my boundless arrogance" .

@PersimmonTI I could added have a third choice: “weekend tweets predicting Monday deals.” 😉

What’s more annoying?

@JamesEKrause That worked. Thanks!

@thisworldstinks I clicked on the link after posting and it worked for me. Try this one. stifel.com/newsletters/in…

For #biotech investing, I tend to rely solely on myself for due diligence and critical evaluation of biotech companies. But analyst reports can be of substantial help is assessing competition. Recently Stifel came out with a tome on the future of biotech and medical innovation, that I found to be quite helpful. Here are a couple of snips, a quote from the article, and a link to the report. "The key fundamental of the bioscience sector is the exponential growth of scientific knowledge and its application. This has been the result of a long historic Enlightenment that began with Descartes, Galileo and many other brave souls. And despite current political discourse, the main dividends of the Enlightenment lay ahead of us. Progress in the understanding of biology is going to be of primary importance to humankind. It’s not about pharmaceuticals, medical devices or life sciences tools. These are industries that commercialize the products of knowledge. It’s the knowledge itself that is going to change humanity." stifel.com/newsletters/in…

@Biohazard3737 The problem with Cathie is double - she is not JUST contra, she is also jinx.

@jfais20 Have a look at $AFMD. I would take $XFOR any day over $AFMD.

$XFOR (NP) Shares outstanding: March 2020- 16M March 2023- 122M 2 months later, top it off with another 43M shares (to be fair, no discount) I like mavorixafor's prospects (fast path to market via WHIM, broader opportunity in CN & other indications) But this mgmt team...

Who were the winners and losers of #ASH22? Spot the Taylor Swift references in this story by @ByMadeleineA @EdwinElmhirst and me evaluate.com/vantage/articl… $GLYC $ACLX $BLUE $ACET $GRCL $AFMD

@Biohazard3737 Great call(s). Gimme 6 more for 2023.

Not being mean but realistically, anything that @dhovekamp42 or @RNAiAnalyst likes is always an easy short. $AFMD $PIRS $NVAX $EIGR

Last trading day before data. Wonder why nobody cares $AFMD?